Adicet Bio (ACET) | Financial Analysis & Statements
Adicet Bio, Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-31.9M
Net Income
-30.5M
EPS (Diluted)
$-2.94
Balance Sheet Metrics
Total Assets
192.4M
Total Liabilities
33.1M
Shareholders Equity
159.2M
Debt to Equity
0.21
Cash Flow Metrics
Operating Cash Flow
-22.8M
Free Cash Flow
-20.9M
Revenue & Profitability Trend
Adicet Bio Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25.0M | 9.7M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 99.1M | 99.3M | 106.0M | 71.2M | 48.9M |
| Selling, General & Administrative | 23.0M | 28.3M | 26.5M | 26.3M | 22.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 122.1M | 127.6M | 132.6M | 97.5M | 71.2M |
| Operating Income | -122.1M | -127.6M | -132.6M | -72.6M | -61.4M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | -290.3% | -631.4% |
| Non-Operating Items | |||||
| Interest Income | 5.8M | 10.7M | 10.0M | 3.8M | 91.0K |
| Interest Expense | 36.0K | 4.0K | 25.0K | 80.0K | 176.0K |
| Other Non-Operating Income | -430.0K | -217.0K | -20.0M | -919.0K | -606.0K |
| Pre-tax Income | -116.8M | -117.1M | -142.7M | -69.8M | -62.1M |
| Income Tax | 0 | 0 | 0 | 0 | -125.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -116.8M | -117.1M | -142.7M | -69.8M | -62.0M |
| Net Margin % | 0.0% | 0.0% | 0.0% | -279.3% | -637.2% |
| Key Metrics | |||||
| EBITDA | -110.4M | -110.6M | -117.1M | -67.1M | -60.4M |
| EPS (Basic) | $-16.95 | $-21.28 | $-3.31 | $-1.70 | $-2.00 |
| EPS (Diluted) | $-16.95 | $-21.28 | $-3.31 | $-1.70 | $-2.00 |
| Basic Shares Outstanding | 6891336 | 5491652 | 43042405 | 41080286 | 30952152 |
| Diluted Shares Outstanding | 6891336 | 5491652 | 43042405 | 41080286 | 30952152 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Adicet Bio Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 38.9M | 56.5M | 159.7M | 257.7M | 277.5M |
| Short-term Investments | 119.6M | 119.8M | - | - | 0 |
| Accounts Receivable | - | - | - | 0 | 185.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 320.0K | 474.0K | 457.0K | 336.0K | 2.0K |
| Total Current Assets | 160.9M | 180.1M | 162.3M | 261.0M | 282.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 25.7M | 28.1M | 30.6M | 27.8M | 25.9M |
| Goodwill | - | - | 0 | 38.9M | 38.9M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.9M | 3.3M | 822.0K | 1.2M | 2.0M |
| Total Non-Current Assets | 31.4M | 40.1M | 45.0M | 69.7M | 56.5M |
| Total Assets | 192.4M | 220.2M | 207.3M | 330.7M | 338.9M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.7M | 4.8M | 2.6M | 4.4M | 3.3M |
| Short-term Debt | 3.2M | 3.1M | 3.2M | 2.5M | 1.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 21.5M | 19.4M | 19.3M | 19.7M | 16.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 11.6M | 14.1M | 17.7M | 18.5M | 19.4M |
| Deferred Tax Liabilities | - | - | - | - | 0 |
| Other Non-Current Liabilities | 62.0K | 116.0K | 130.0K | 114.0K | 115.0K |
| Total Non-Current Liabilities | 11.6M | 14.2M | 17.8M | 18.6M | 19.5M |
| Total Liabilities | 33.1M | 33.6M | 37.1M | 38.4M | 35.8M |
| Equity | |||||
| Common Stock | 10.0K | 8.0K | 4.0K | 4.0K | 4.0K |
| Retained Earnings | -614.7M | -497.9M | -380.8M | -238.1M | -168.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 159.2M | 186.6M | 170.2M | 292.3M | 303.1M |
| Key Metrics | |||||
| Total Debt | 14.7M | 17.2M | 20.9M | 21.0M | 20.9M |
| Working Capital | 139.4M | 160.7M | 143.0M | 241.3M | 266.1M |
Balance Sheet Composition
Adicet Bio Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -116.8M | -117.1M | -142.7M | -69.8M | -62.0M |
| Depreciation & Amortization | 6.4M | 6.5M | 6.1M | 2.6M | 1.5M |
| Stock-Based Compensation | 14.3M | 22.2M | 20.3M | 17.1M | 12.5M |
| Working Capital Changes | -2.1M | -2.2M | -1.4M | -4.2M | -8.5M |
| Operating Cash Flow | -94.8M | -87.4M | -114.9M | -51.8M | -54.8M |
| Investing Activities | |||||
| Capital Expenditures | -1.7M | -1.1M | -4.5M | -16.8M | -13.0M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -140.9M | -129.1M | - | - | 0 |
| Investment Sales | 145.0M | 11.0M | - | 0 | 10.2M |
| Investing Cash Flow | 2.4M | -119.2M | -4.5M | -16.8M | -2.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -150.0K | - | - | - | - |
| Financing Cash Flow | 74.9M | 110.8M | -150.0K | 39.8M | 237.9M |
| Free Cash Flow | -97.0M | -93.5M | -98.2M | -61.5M | -64.1M |
| Net Change in Cash | -17.5M | -95.9M | -119.5M | -28.8M | 180.3M |
Cash Flow Trend
Adicet Bio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.47
Forward P/E
-2.40
Price to Book
0.54
PEG Ratio
0.01
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-67.55%
Return on Assets
-37.00%
Financial Health
Current Ratio
7.47
Debt to Equity
9.26
Beta
1.58
Per Share Data
EPS (TTM)
$-16.95
Book Value per Share
$14.83
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ACET | 75.8M | -0.47 | 0.54 | -67.55% | 0.00% | 9.26 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






